AU2008313459B2 - Diagnostic, predictive and prognostic testing for cancer - Google Patents

Diagnostic, predictive and prognostic testing for cancer Download PDF

Info

Publication number
AU2008313459B2
AU2008313459B2 AU2008313459A AU2008313459A AU2008313459B2 AU 2008313459 B2 AU2008313459 B2 AU 2008313459B2 AU 2008313459 A AU2008313459 A AU 2008313459A AU 2008313459 A AU2008313459 A AU 2008313459A AU 2008313459 B2 AU2008313459 B2 AU 2008313459B2
Authority
AU
Australia
Prior art keywords
biomarker
cancer
level
aurora
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008313459A
Other languages
English (en)
Other versions
AU2008313459A1 (en
Inventor
Kai Stoeber
Gareth Hayden Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Cancer Diagnostics Ltd
Original Assignee
Cambridge Cancer Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Cancer Diagnostics Ltd filed Critical Cambridge Cancer Diagnostics Ltd
Publication of AU2008313459A1 publication Critical patent/AU2008313459A1/en
Application granted granted Critical
Publication of AU2008313459B2 publication Critical patent/AU2008313459B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008313459A 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer Ceased AU2008313459B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0720113.0A GB0720113D0 (en) 2007-10-15 2007-10-15 Diagnostic, prognostic and predictive testing for cancer
GB0720113.0 2007-10-15
PCT/GB2008/003501 WO2009050461A1 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer

Publications (2)

Publication Number Publication Date
AU2008313459A1 AU2008313459A1 (en) 2009-04-23
AU2008313459B2 true AU2008313459B2 (en) 2013-01-24

Family

ID=38813827

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008313459A Ceased AU2008313459B2 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer

Country Status (11)

Country Link
US (3) US8512716B2 (cg-RX-API-DMAC7.html)
EP (1) EP2208070B1 (cg-RX-API-DMAC7.html)
JP (2) JP5559056B2 (cg-RX-API-DMAC7.html)
CN (1) CN101896819A (cg-RX-API-DMAC7.html)
AU (1) AU2008313459B2 (cg-RX-API-DMAC7.html)
CA (1) CA2702653A1 (cg-RX-API-DMAC7.html)
DK (1) DK2208070T3 (cg-RX-API-DMAC7.html)
ES (1) ES2395890T3 (cg-RX-API-DMAC7.html)
GB (1) GB0720113D0 (cg-RX-API-DMAC7.html)
PT (1) PT2208070E (cg-RX-API-DMAC7.html)
WO (1) WO2009050461A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921873D0 (en) * 2009-12-15 2010-01-27 Cytosystems Ltd Assay
MX361944B (es) * 2010-07-23 2018-12-19 President And Fellows Of Harvard College Star Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
BR112015027937A2 (pt) * 2013-05-09 2017-07-25 Procter & Gamble método e sistema para avaliação de uma condição de saúde
CN103592444A (zh) * 2013-11-27 2014-02-19 中国人民解放军沈阳军区总医院 一种检测乳腺癌中cyclin G1蛋白表达并进行预后评估的方法
WO2015187498A1 (en) * 2014-06-01 2015-12-10 Novazoi Theranostics, Inc. Compositions and methods for prognosis and treatment of neoplasm
WO2016131875A1 (en) * 2015-02-17 2016-08-25 Biontech Diagnostics Gmbh Methods and kits for the molecular subtyping of bladder cancer
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
JP6854246B2 (ja) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド 尿サンプルの分析方法
CN105986034A (zh) * 2016-06-15 2016-10-05 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
CN108344868B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人早期胚胎的发育分期中的应用
CN108344867B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人卵母细胞成熟分期中的应用
CN111187833A (zh) * 2018-11-14 2020-05-22 上海生物芯片有限公司 Plk1和bub1b基因联合作为肺癌生物标志物的用途
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method
CN109988708B (zh) * 2019-02-01 2022-12-09 碳逻辑生物科技(中山)有限公司 一种用于对患有结肠直肠癌的患者进行分型的系统
CN110846413B (zh) * 2019-11-23 2023-05-26 中南大学湘雅三医院 Mafg/mafg-as1/mafg正反馈环作为靶位点检测试剂的应用
CN114019163B (zh) * 2021-11-02 2024-07-23 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
WO2023150578A2 (en) * 2022-02-01 2023-08-10 4D Path Inc. Systems and methods for image-based disease characterization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329177A1 (de) * 1993-08-30 1995-03-02 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Serin-Threonin-Kinasen
DE19915057A1 (de) * 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
EP2163650B1 (en) * 2004-04-09 2015-08-05 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1737982A4 (en) * 2004-04-14 2009-09-23 Harvard College NUCLEIC ACID PROGRAMMABLE PROTEIN NETWORKS
KR20070061893A (ko) * 2004-09-22 2007-06-14 트리패스 이미징, 인코포레이티드 유방암 예후를 평가하기 위한 방법 및 조성물
WO2006087557A1 (en) * 2005-02-18 2006-08-24 Astrazeneca Ab METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS
EP1968579A1 (en) * 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
WO2007079128A1 (en) * 2005-12-30 2007-07-12 Ventana Medical Systems, Inc. Na+, k+-atpase expression in cervical dysplasia and cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOING J J ET AL (2002), GUT, vol. 50, no. 3, pages 373-377 *
HETTY A ET AL (2005) BRITISH JOURNAL OF CANCER vol. 93, no. 11, pages 1295-1300 *
SCOTT I S ET AL (2005), NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY vol. 31, no. 5, pages 455-466 *

Also Published As

Publication number Publication date
US20180223366A1 (en) 2018-08-09
WO2009050461A1 (en) 2009-04-23
PT2208070E (pt) 2013-01-08
JP2014095726A (ja) 2014-05-22
US8512716B2 (en) 2013-08-20
US20100285474A1 (en) 2010-11-11
CN101896819A (zh) 2010-11-24
US20140154680A1 (en) 2014-06-05
ES2395890T3 (es) 2013-02-15
GB0720113D0 (en) 2007-11-28
EP2208070B1 (en) 2012-10-03
JP5559056B2 (ja) 2014-07-23
AU2008313459A1 (en) 2009-04-23
CA2702653A1 (en) 2009-04-23
DK2208070T3 (da) 2012-12-17
JP5837630B2 (ja) 2015-12-24
EP2208070A1 (en) 2010-07-21
JP2011501809A (ja) 2011-01-13

Similar Documents

Publication Publication Date Title
AU2008313459B2 (en) Diagnostic, predictive and prognostic testing for cancer
Wangsa et al. Near-tetraploid cancer cells show chromosome instability triggered by replication stress and exhibit enhanced invasiveness
Greene et al. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients
Schuurbiers et al. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound-and endobronchial ultrasound-guided fine needle cytological aspirates
Heckl et al. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium
Ho et al. Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma
Banet et al. HER-2 amplification in uterine serous carcinoma and serous endometrial intraepithelial carcinoma
US20120245051A1 (en) Objective, quantitative method to predict histological subtype in non-small cell lung cancer
Li et al. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma
Pierssens et al. Chromosome instability in tumor resection margins of primary OSCC is a predictor of local recurrence
Moreira et al. Molecular characterization by immunocytochemistry of lung adenocarcinoma on cytology specimens
Liu et al. Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer
JP4848355B2 (ja) 臨床診療における新規増殖マーカーおよび癌の予後または診断のためのそれらの用途
Wu et al. Combining the tyrosine kinase inhibitor cabozantinib and the mTORC1/2 inhibitor sapanisertib blocks ERK pathway activity and suppresses tumor growth in renal cell carcinoma
WO2013035095A1 (en) Methods for diagnosing cancer
Bai et al. DUSP7 inhibits cervical cancer progression by inactivating the RAS pathway
KR20240156639A (ko) 암 진단 및 prmt5 억제제에 의한 치료
US8071815B2 (en) CTIP2 expression in squamous cell carcinoma
GB2519830A (en) Methods for monitoring treatment response and relapse in ovarian cancer
Suwiwat et al. Expression of CD44v6 and RCAS1 in uterine cervical carcinoma infected with human papillomavirus and its effect on cell proliferation and differentiation
Davidson et al. Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma
Liu et al. Expression of p53, p16 and cyclooxygenase‐2 in esophageal cancer with tissue microarray
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
Mamat@ Yusof et al. Gene expression and soluble protein level of PD-1 and its ligands (PD-L1 and PD-L2) in endometrial cancer
JP2009524048A (ja) Ｓｈｃタンパク質を使用して消化管および他の癌の再発の予後を診断するための方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired